【其他高分选 063】

BC

PMID: 39226654

IF:12.8

Genetically engineered CD276-anchoring biomimetic nanovesicles target senescent escaped tumor cells to overcome chemoresistant and immunosuppressive breast cancer

PMID:39227105

IF:10.7

Self-enhanced PTX@HSA-HA loaded functionalized injectable hydrogel for effective local chemo-photothermal therapy in breast cancer

PMID:39226766

IF:10.3

Carcinogenic industrial air pollution and postmenopausal breast cancer risk in the National Institutes of Health AARP Diet and Health Study

PMID:39231944

IF:14.7

Large-scale analysis of whole genome sequencing data from formalin-fixed paraffin-embedded cancer specimens demonstrates preservation of clinical utility

PMID:39232146

IF:50.5

Breast cancer blocked by multiple natural lines of defence

PMID:39235813

IF:10.5

Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening

PMID:39235716

IF:10

Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier-Free Nanodrugs for Breast Cancer Immunotherapy

PMID:39233557

IF:27.4

Tumor-Homing Phage Nanofibers for Nanozyme-Enhanced Targeted Breast Cancer Therapy

PMID:39244215

IF:10.3

Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade

PMID:39243601

IF:15.8

crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer

PMID:39243069

IF:11.4

Why make it if you can take it: review on extracellular cholesterol uptake and its importance in breast and ovarian cancers

PMID:39243032

IF:27.7

NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer

PMID:39242032

IF:10.5

Rational design of a poly-L-glutamic acid-based combination conjugate for hormone-responsive breast cancer treatment

PMID:39241962

IF:56.7

Is adjuvant ribociclib ready for prime time?

CRC

PMID:39227578

IF:14.7

Citrullination modulation stabilizes HIF-1α to promote tumour progression

PMID:39234613

IF:14.7

Endoplasmic reticulum-targeted delivery of celastrol and PD-L1 siRNA for reinforcing immunogenic cell death and potentiating cancer immunotherapy

PMID:39235834

IF:12.5

Role of microenvironment characteristics and MRI radiomics in the risk stratification of distant metastases in rectal cancer: A diagnostic study

PMID:39243766

IF:30.9

Blood tests for colorectal cancer: practical or premature?

PMID:39242191

IF:23

Epidemiology of gastrointestinal cancers: a systematic analysis from the Global Burden of Disease Study 2021

GC

PMID:39237127

IF:23

Where are we with gastric cancer screening in Europe in 2024?

PMID:39237761

IF:72.5

Intercepting gastric cancer

PMID:39244216

IF:10.3

Intratumoral CXCL13+ CD160+ CD8+ T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer

HCC

PMID:39228069

IF:14

Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors

PMID:39232431

IF:10.7

Aggregation-induced emission: Application in diagnosis and therapy of hepatocellular carcinoma

PMID:39234824

IF:14.3

m(6)A-Dependent ITIH1 Regulated by TGF-beta Acts as a Target for Hepatocellular Carcinoma Progression

PMID:39239526

IF:12.4

DAB2 + macrophages support FAP + fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer

PMID:39241773

IF:11.7

Five miRNAs identified in fucosylated extracellular vesicles as non-invasive diagnostic signatures for hepatocellular carcinoma

PMID: 39242192

IF:23

Cholesterol's new tricks propel MASH-HCC: impact in immunotherapy

PMID: 39242496

IF:27.7

Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma

PMID: 39243773

IF:30.9

Natural history and progression of metabolic dysfunction-associated steatotic liver disease

PMID:39243943

IF:11.4

Metabolic phenotyping combined with transcriptomics metadata fortifies the diagnosis of early-stage Hepatocellular carcinoma

LC

PMID:39231392

IF:42.1

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years

PMID:39231239

IF:15.8

PTPRT loss enhances anti-PD-1 therapy efficacy by regulation of STING pathway in non-small cell lung cancer

PMID:39232758

IF:27.7

The prognostic effect of infiltrating immune cells is shaped by proximal M2 macrophages in lung adenocarcinoma

PMID:39231544

IF:10.3

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy

PMID: 39231545

IF:10.3

Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study

PMID: 39235774

IF:22.5

Inpatient Care and Outcomes Among People With Cancer Experiencing Homelessness

PMID:39234811

IF:14.3

Targeting Dual Immune Checkpoints PD-L1 and HLA-G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer

PMID:39232927

IF:12.8

Cell-free and extrachromosomal DNA profiling of small cell lung cancer

PMID:39237931

IF:10.6

Apoptosis and cuproptosis Co-activated Copper-based metal-organic frameworks for cancer therapy

PMID:39237261

IF:10.3

scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC

PMID:39236630

IF:12.8

Liposomes-enabled cancer chemoimmunotherapy

PMID:39239344

IF:12

Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer RadiotherapyCardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy

PMID:39239328

IF:12

Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer: An NI-HEART Analysis

PMID:39244641

IF:12.1

Prevention of Prostate Cancer Metastasis by a CRISPR-delivering Nanoplatform for Interleukin-30 Genome Editing

PMID:39243941

IF:11.4

Serum taurine affects lung cancer progression by regulating tumor immune escape mediated by the immune microenvironment